Applicability of the Monocyte Activation Test (MAT) in Brazil: the importance of its use as a test for the detection of pyrogens in the quality control of injectable products

Authors

  • Cristiane Caldeira da Silva Instituto Nacional de Controle de Qualidade em Saúde, Centro Brasileiro para Validação de Métodos Alternativos (BraCVAM INCQS/FIOCRUZ), Rio de Janeiro Author http://orcid.org/0000-0002-1038-6379
  • Mayara Cruz Instituto Nacional de Controle de Qualidade em Saúde (INCQS/FIOCRUZ), Rio de Janeiro Author
  • João Carlos Freitas Instituto Nacional de Controle de Qualidade em Saúde (INCQS/FIOCRUZ), Rio de Janeiro Author
  • Octavio Presgrave Instituto Nacional de Controle de Qualidade em Saúde, Centro Brasileiro para Validação de Métodos Alternativos (BraCVAM INCQS/FIOCRUZ), Rio de Janeiro Author
  • Aurea Moraes Instituto Oswaldo Cruz (IOC/FIOCRUZ), Rio de Janeiro Author
  • Isabella Fernandes Delgado Instituto Nacional de Controle de Qualidade em Saúde (INCQS/FIOCRUZ), Rio de Janeiro Author

DOI:

https://doi.org/10.3395/2317-269x.00519

Keywords:

Monocyte Activation Test, Rabbit Pyrogen Test, Pharmacopoeias, Biological products

Abstract

Monocyte Activation Test (MAT) is thought to be a good replacement for rabbit pyrogen test (RPT); however, MAT remains controversial. MAT was not adequately evaluated in a sufficient number of products, and there is no sufficient data that support the ability of MAT to detect non-endotoxin pyrogens. Furthermore, MAT was used subject to validation for each specific product. The aim of this study was to identify in main pharmacopoeias, whose monographs require pyrogenicity tests, and propose those products for which only the rabbit pyrogen test is required to be used as a kick-off study for future studies. Products’ monographs in pharmacopeias in the United States, Europe, and Brazil that are recommended for RPT or Bacterial Endotoxins Test (BET) are as follows. RPT: 20 in American, 37 in European, and 28 in Brazilian pharmacopoeias. BET: 619 in American, 157 in European, and 41 in Brazilian pharmacopoeias. Four products require pyrogenicity testing in three pharmacopoeias. Both RPT and BET are recommended by six monographs in Brazilian pharmacopeias and 15 in European pharmacopoeias. In Brazilian pharmacopoeias most are biological. These products should be the first to be tested for their applicability to MAT because they are currently tested mainly by RPT.

Downloads

Download data is not yet available.

Author Biographies

  • Cristiane Caldeira da Silva, Instituto Nacional de Controle de Qualidade em Saúde, Centro Brasileiro para Validação de Métodos Alternativos (BraCVAM INCQS/FIOCRUZ), Rio de Janeiro
    Instituto Nacional de Controle da Qualidade em Saúde. Departamento de farmacologia e Toxicologia. Área: Toxicologia
  • Mayara Cruz, Instituto Nacional de Controle de Qualidade em Saúde (INCQS/FIOCRUZ), Rio de Janeiro
    Instituto Nacional de Controle da Qualidade em Saúde. Departamento de farmacologia e Toxicologia. Área: Toxicologia
  • João Carlos Freitas, Instituto Nacional de Controle de Qualidade em Saúde (INCQS/FIOCRUZ), Rio de Janeiro
    Instituto Nacional de Controle da Qualidade em Saúde. Departamento de farmacologia e Toxicologia. Área: Toxicologia
  • Octavio Presgrave, Instituto Nacional de Controle de Qualidade em Saúde, Centro Brasileiro para Validação de Métodos Alternativos (BraCVAM INCQS/FIOCRUZ), Rio de Janeiro
    Instituto Nacional de Controle da Qualidade em Saúde. Departamento de farmacologia e Toxicologia. Área: Toxicologia

Published

2015-08-26

Issue

Section

Articles

How to Cite

Applicability of the Monocyte Activation Test (MAT) in Brazil: the importance of its use as a test for the detection of pyrogens in the quality control of injectable products. (2015). Health Surveillance under Debate: Society, Science & Technology , 3(3), 41-46. https://doi.org/10.3395/2317-269x.00519

Most read articles by the same author(s)

1 2 3 4 > >>